Mitochondrial myopathy and sideroblastic anemia (MLASA): A Patient Guide
At a Glance
MLASA is an ultra-rare genetic condition that disrupts mitochondrial energy production and causes muscle weakness, lactic acidosis, and sideroblastic anemia. Ongoing care coordinates blood, heart, lung, and iron monitoring and includes plans for illness and activity.
Mitochondrial Myopathy, Lactic Acidosis, and Sideroblastic Anemia (MLASA) is an ultra-rare genetic condition that affects the way your body produces and uses energy. At its core, MLASA is a disorder of the mitochondria, the microscopic power plants found in nearly every cell of the body. When these power plants cannot function correctly, the body struggles to fuel its most energy-intensive systems, particularly the muscles and the blood-forming tissues [1][2].
This underlying energy failure manifests as a “triad” of symptoms: myopathy (muscle weakness and exercise intolerance), lactic acidosis (a buildup of lactic acid in the blood), and sideroblastic anemia (a specific type of low blood count where the body cannot properly use iron to make hemoglobin in developing red blood cells) [3][4].
The condition is caused by specific pathogenic variants in genes that provide instructions for building mitochondrial proteins. The two most common forms are MLASA1, which involves the PUS1 gene, and MLASA2, which involves the YARS2 gene [5][6]. Because these genes are essential for the “delivery system” that builds the energy-producing machinery within your cells, their failure leads to a systemic energy crisis. This biological mechanism explains why symptoms can appear in diverse parts of the body, from the muscles used for walking and breathing to the heart and the bone marrow [2][7].
Because MLASA is exceptionally rare, it requires a specialized, multidisciplinary approach to care. No single doctor can manage the complexities of the condition alone; instead, a team of experts—including metabolic geneticists, hematologists, cardiologists, and pulmonologists—must work together to monitor the health of your heart, lungs, and blood. Living with MLASA means learning to balance activity with rest, proactively managing iron levels (which is necessary even if you do not receive transfusions, as ineffective blood production causes iron loading), and taking extra precautions during illnesses to prevent metabolic stress. While the diagnosis is life-changing, understanding the biological foundation of the disease allows you and your care team to build a plan focused on stability, safety, and supportive care [8][3].
In this guide
6 chapters
Building a Foundation: Understanding Your MLASA Diagnosis
Learn what an MLASA diagnosis means, including mitochondrial myopathy, lactic acidosis, sideroblastic anemia, symptom onset, and heart and lung monitoring.
Biology, Subtypes, and Look-Alikes: Why the Details Matter
Learn how MLASA1 and MLASA2 differ, how PUS1 and YARS2 variants affect muscle and blood, and how doctors distinguish MLASA from similar mitochondrial disorders
The Path to Certainty: Getting an Accurate Diagnosis
Learn how MLASA is diagnosed with PUS1 or YARS2 testing, copy-number analysis, bone marrow findings, muscle biopsy results, and key mitochondrial studies.
Treatment and Daily Management: Living with MLASA
Learn daily management for MLASA, including transfusions, iron chelation, energy pacing, sick-day planning, heart and lung monitoring, and research therapies.
Assembling Your Team: Specialized Care and Safety Precautions
Learn how a specialized MLASA care team manages surgery, infections, metabolic crises, anesthesia risks, and pregnancy through individualized safety plans.
Monitoring, Prognosis, and Warning Signs: Your Safety Plan
Learn how MLASA monitoring tracks heart, breathing, blood, and iron health, what prognosis factors mean, and which warning signs require emergency care.
Common questions in this guide
What does MLASA stand for, and what problems does it cause?
What genes are associated with MLASA?
Which specialists are usually involved in MLASA care?
Why is iron monitoring important even without blood transfusions?
What should we do if someone with MLASA develops a fever or virus?
How can daily activity be managed with MLASA?
Get notified when new evidence is published on Mitochondrial myopathy and sideroblastic anemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Myopathy, lactic acidosis and sideroblastic anemia 1 (MLASA1): A 25-year follow-up.
Woods J, Cederbaum S
Molecular genetics and metabolism reports 2019; (21()):100517 doi:10.1016/j.ymgmr.2019.100517.
PMID: 31641589 - 2
Mitochondrial tRNA pseudouridylation governs erythropoiesis.
Wang B, Shi D, Yang S, et al.
Blood 2024; (144(6)):657-671 doi:10.1182/blood.2023022004.
PMID: 38635773 - 3
Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.
Sommerville EW, Ng YS, Alston CL, et al.
JAMA neurology 2017; (74(6)):686-694 doi:10.1001/jamaneurol.2016.4357.
PMID: 28395030 - 4
A novel and apparent de novo ALAS2 missense variant associated with congenital sideroblastic anemia.
Cai J, Liu T, Huang Y, et al.
Frontiers in pediatrics 2024; (12()):1411676 doi:10.3389/fped.2024.1411676.
PMID: 39281190 - 5
The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.
Riley LG, Heeney MM, Rudinger-Thirion J, et al.
Haematologica 2018; (103(12)):2008-2015 doi:10.3324/haematol.2017.182659.
PMID: 30026338 - 6
Respiratory complex I deficiency caused by a novel multi-exonic PUS1 deletion.
Yuan JH, Higuchi Y, Ando M, et al.
Journal of human genetics 2026; (71(5)):275-282 doi:10.1038/s10038-025-01437-8.
PMID: 41361485 - 7
Pseudouridine synthase 1 deficient mice, a model for Mitochondrial Myopathy with Sideroblastic Anemia, exhibit muscle morphology and physiology alterations.
Mangum JE, Hardee JP, Fix DK, et al.
Scientific reports 2016; (6()):26202 doi:10.1038/srep26202.
PMID: 27197761 - 8
Correlation of MLASA2 Clinical Phenotype and Survival with Mt-TyrRS Protein Damage: Linking Systematic Review, Meta-Analysis and 3D Hotspot Mapping.
Villafan-Bernal JR, Martínez-Hernández A, García-Ortiz H, et al.
Current issues in molecular biology 2026; (48(1)) doi:10.3390/cimb48010095.
PMID: 41614925
This MLASA guide is for informational purposes only and does not constitute medical advice. Your metabolic genetics and other specialists should interpret genetic findings and tailor care for you or your child.